Venous access port assembly with X-ray discernable indicia

Description

FIELD OF THE INVENTION

This relates to the field of medical devices and more particularly to venous access ports for the infusion of fluids into a patient and/or withdrawal of fluids from a patient.

BACKGROUND OF THE INVENTION

Venous access ports for the infusion and/or withdrawal of fluids from a patient are well-known, secured to the proximal end of an implanted catheter. These ports are typically used for drug infusion or for withdrawal of small amounts of blood, where large flows at fluid are not required. The ports are assemblies of a needle-impenetrable housing with a discharge port in fluid communication with a catheter and a reservoir within t e port housing, and provide a subcutaneous self-sealing septum that defines an access site for multiple needle sticks through the covering skin tissue of the patient, through the septum, and into the reservoir, without the need to continuously search for new access sites. Examples of such ports are disclosed, for example, in U.S. Pat. Nos. 4,704,103; 4,762,517; 4,778,452; 5,185,003; 5,213,574 and 5,637,102.

It is desired to provide a venous access port assembly that provides for a radiologist, radiology technologist, nurse, and ultimately a medical practitioner to be able to discern an important property of the port assembly after the port assembly has been implanted into a patient.

SUMMARY OF THE INVENTION

An embodiment of the present invention is related to a venous access port having a housing and a septum, providing an interior reservoir and a passageway extending from the reservoir through a stem of a discharge port to establish fluid communication with a proximal end of a catheter lumen to which the port assembly is secured prior to placement of the assembly into a patient. The port may optionally have more than one reservoir and associated septum. An embodiment of the present invention includes the incorporation of X-ray discernable indicia onto a venous access port that is discernible under X-ray examination to provide information concerning the nature or key attribute of the venous access port, so that the practitioner, subsequent to the date of implantation thereof, can determine that nature or key attribute under X-ray examination. One such key attribute in particular would be for example that the venous access port is rated to be used for power injection such as of contrast fluid, wherein for example the letters “CT” (for “computed tomography”, or “contrast enhanced computed tomography”) would be provided that are of radiopaque material, or are cutouts through radiopaque material. The attribute in this example is the property of the port being adapted to withstand high pressures that are used for injection of contrast fluid into a patient, and the letters “CT” would be understood in medical practice to indicate that the port is suitable for the high pressure injection of contrast fluid.

In one embodiment, a disc of radiopaque material includes cutouts of letters “CT” (although other indicia may be utilized) through the body of the disc. In another embodiment, discrete letters “CT” (although other indicia may be utilized) are provided of radiopaque material. With either embodiment, the disc or letters may be insert molded within the housing base bottom wall, or they may be affixed to the bottom surface of the housing base, preferably within complementary recesses thereinto, in such a manner that the letters “CT” are readable from above the port assembly in an X-ray.

BRIEF DESCRIPTION OF THE DRAWINGS

The accompanying drawings, which are incorporated herein and constitute part of this specification, illustrate embodiments of the invention, and, together with the general description given above and the detailed description given below, serve to explain the features of the embodiments of the invention. In the drawings:

FIGS. 1 and 2 are an isometric view and a plan view of a venous access port in accordance with an exemplary embodiment of the present invention;

FIGS. 3 and 4 are cross-sectional views of the port of FIGS. 1 and 2 taken along lines 3-3 and lines 4-4 of FIG. 1, respectively;

FIG. 5 is an isometric view of the needle-impenetrable housing base of the venous access port of FIG. 1;

FIGS. 6 and 7 are transverse cross-sectional and longitudinal cross-sectional views of the housing base of FIG. 5;

FIG. 8 is an isometric view of a first embodiment of X-ray discernable indicia, being a disc of radiopaque material having letters cut out thereof;

FIGS. 9 to 11 are bottom, cross-sectional, and top views of the port assembly of FIGS. 1 to 7 having the disc of FIG. 8 affixed to the housing base of FIGS. 6 and 7 and within a shallow recess into its bottom surface, with silicone covering molded thereover, and the indicia being shown in dashed lines in FIGS. 9 and 11;

FIG. 12 is a cross-sectional view of an alternate embodiment of the housing base having the disc of FIG. 8 insert molded embedded within the bottom wall of the base;

FIG. 13 is an isometric view of a second embodiment of radiopaque indicia, comprising a set of discrete letters of radiopaque material;

FIGS. 14 and 15 are a bottom view and a cross-sectional view of a port assembly of FIGS. 1 to 7 having the discrete letters of FIG. 13 insert molded into the bottom wall of the housing base, with FIG. 15 taken along lines 15-15 of FIG. 13; and

FIGS. 16 to 18 are a bottom view, cross-sectional view, and an isometric bottom view of a port assembly of FIGS. 1 to 7 having the discrete letters of FIG. 13 affixed to the bottom surface of the housing base, shown within respective recesses thereinto, with a silicone covering molded thereover, with FIG. 17 taken along lines 17-17 of FIG. 16.

DETAILED DESCRIPTION OF THE INVENTION

Certain terminology is used herein for convenience only and is not to be taken as a limitation on the present invention. The terms “distal” and “proximal” refer, respectively, to directions closer to and away from the insertion tip of a catheter in an implantable catheter assembly. The terminology includes the words specifically mentioned, derivatives thereof, and words of similar import. The embodiments illustrated below are not intended to be exhaustive or to limit the invention to the precise form disclosed. These embodiments are chosen and described to best explain the principle of the invention and its application and practical use and to enable others skilled in the art to best utilize the invention.

Venous access port assembly 10 of FIGS. 1 to 4 includes a housing 12 and a septum 14, with a discharge port 16 extending from a distal end 18 of the port assembly 10 to be attached securely and sealingly to the proximal end of a catheter (not shown). A passageway 20 extends from the interior reservoir 22 to the distal tip opening 24 of discharge port 16. A recess 26 is seen to be provided along both sides of discharge port 16, facilitating insertion of the discharge port 16 into the catheter lumen and providing a clearance for a locking sleeve or clamp (not shown) utilized to compress the catheter lumen wall against the exterior surface of the discharge port 16 for assured sealed connection of the catheter with the port assembly 10.

With reference now to FIGS. 3 to 7, the interior of the port assembly 10 is shown to provide an interior reservoir 22. Housing 12 is shown to include a housing base 28 of needle-impenetrable material that includes a well 30 having a bottom floor 32 and side walls 34 that define the interior reservoir 22 beneath septum 14. Bottom floor 32 may be convex or elevated (not shown) toward the center of the reservoir, if desired. Housing base 28 includes a base flange 36 extending radially outwardly from the bottom of well 30, and base flange 36 includes openings 38,40 that serve to enable suturing to the patient upon placement of the venous access port and the attached catheter into the patient.

As shown in FIGS. 3 and 4, a skirt 42 is overmolded about housing base 28 and may be of silicone elastomer. It is seen that skirt 42 encapsulates the outer surfaces of the bottom wall 44 and the bottom portion of the side walls 46 of housing base 28, and is shown to fill in the suture holes 38,40; but since the material is silicone elastomer, suturing is possible since the suturing needle can easily be inserted through the material of skirt 42 and through the suture holes, and thereafter the filled openings provide minimal opportunity for ingrowth of patient tissue into the openings.

Also seen in FIGS. 1 to 4 is cap 48, which secures to housing base 28 to in turn secure septum 14 in position in the port assembly 10. Preferably, skirt 42 is insert molded onto base flange 36 of housing base 28 before cap 48 is secured to the upper portion of housing base 28 to secure the septum in position. It is seen in FIGS. 4 and 7 that discharge port 16 is integral with housing base 28 as is preferable. Discharge port 16 is shown to have a pair of annular ridges 50 that facilitate with the mechanical connection of the catheter proximal end with the port assembly 10. Housing base 28 includes a septum seat 52 extending into the top of well 30, into which a flange of the septum will be seated, preferably under radially inward compression. Housing base 28 has a bottom outer surface 54.

FIG. 8 shows a first embodiment of a component of radiopaque material of the present invention in the form of a disc 100, such as of titanium. Cutouts 102 are formed through the disc body, shown in FIG. 8 as the alphabetical letters “CT”. Disc 100 is affixed to the bottom surface 104 of housing base 106 in FIGS. 9 and 10, preferably within a complementary shallow recess 108 thereinto. A skirt 110 of silicone material is molded over the housing base, and is transparent so that the letters “CT” are visible from below but in a mirror-image orientation on the bottom outer surface of the housing base (FIG. 9) so that the indicia would appear as “CT” when the X-ray is viewed (FIG. 11), easily discerned by the radiologist or technologist. Centering of the indicia within the region directly beneath the reservoir and septum minimizes any obscuring by the structure of the venous access port assembly, and the indicia may also be easily discernable should the port assembly be at an angle from the horizontal plane of the X-ray.

In FIG. 12, an alternate embodiment of the present invention is shown, in which the disc 100 of FIG. 8 is embedded within the thickness of the bottom wall 130 of the housing base 132, and the X-ray would appear very similar to that shown in FIG. 11 but the indicia would not be visible from below the housing base or the port assembly.

A second embodiment of X-ray discernable indicia 200 is shown in FIG. 13, and is utilized in the port assemblies of FIGS. 14 to 18. In FIG. 13, the indicia comprise a set of discrete indicia elements 202 of radiopaque material, such as being stamped from a sheet of titanium. Again, as is preferred, the indicia comprise the alphabetical letters “C” and “T” and are utilized together as a set. In FIGS. 14 and 15, the discrete elements are embedded into the thickness of the bottom wall 204 of housing base 206, so that they would not be visible from below (see FIG. 14) even though the silicone overmolded skirt 208 is transparent. However, the discrete letters 202 would clearly be visible on an X-ray very similarly to the port assembly shown in FIG. 11. Another manner of using discrete letters 202 is depicted in FIGS. 16 to 18, in which the letters 202 are insert molded along the bottom surface 230 of housing base 232 and recessed thereinto, preferably. With this variant, the radiopaque material may be titanium or may be for example, silicone material having barium sulfate filler. In this case the mirror-image of “CT” would be visible from below as depicted in FIG. 18 after the silicone overmolding of skirt 234 about the exterior of housing base 232.

It will be appreciated by those skilled in the art that changes could be made to the embodiments described above without departing from the broad inventive concept thereof. It is understood, therefore, that this invention is not limited to the particular embodiments disclosed, but it is intended to cover modifications within the spirit and scope of the present invention as defined by the appended claims.

Claims

1. An implantable venous access port assembly, comprising: a needle-penetrable septum; anda housing securing the needle-penetrable septum, at least a portion of the housing comprising radiopaque material, the housing further comprising X-ray discernable indicia to identify an attribute of the access port assembly,wherein the X-ray discernable indicia are cut outs formed through at least a portion of the radiopaque material.
2. The port assembly of claim 1, wherein: a bottom wall of the housing comprises a bottom surface, andthe X-ray discernable indicia are recessed into the bottom surface of the bottom wall, whereby the X-ray discernable indicia are visible by an unaided eye prior to implantation of the port assembly.
3. The port assembly of claim 2, wherein the housing further comprises a generally planar portion of radiopaque material recessed into the bottom surface of the bottom wall, the generally planar portion of radiopaque material comprising one or more cutouts forming the X-ray discernable indicia that visually indicate, under X-ray examination, the attribute of the port assembly.
4. The port assembly of claim 2, wherein the X-ray discernable indicia comprise one or more discrete elements of radiopaque material separately recessed into the bottom surface of the bottom wall, the one or more discrete elements visually indicating, under X-ray examination, the attribute of the port assembly.
5. The port assembly of claim 1, wherein: the attribute of the port assembly is a pressure property of the port assembly, andthe X-ray discernable indicia visually indicate, under X-ray examination, the pressure property of the port assembly.
6. The port assembly of claim 5, wherein the X-ray discernable indicia visually indicate, under X-ray examination, that the port assembly is rated to be used for power injection.
7. The port assembly of claim 5, wherein the X-ray discernable indicia visually indicate, under X-ray examination, that the port assembly is adapted to withstand high pressures used for injection of contrast fluid.
8. The port assembly of claim 1, wherein the radiopaque material comprises titanium.
9. The port assembly of claim 1, wherein the radiopaque material comprises silicone and a barium sulfate filler.
10. The port assembly of claim 1, wherein the housing further comprises a skirt formed from radiotransparent material molded around at least a portion of the housing.
11. The port assembly of claim 1, wherein the X-ray discernable indicia comprise one or more alphabetical letters.
12. The port assembly of claim 11, wherein the one or more alphabetical letters comprise the letters “C” and “T”.
13. An implantable venous access port assembly, comprising: a needle-penetrable septum; anda housing comprising a well for securing the needle-penetrable septum, the housing further comprising X-ray discernable indicia formed through a portion of the port assembly; andwherein at least one X-ray discernable indicia is visible in a mirror-image orientation from at least one of a top and a bottom of the port assembly.
14. The port assembly of claim 13, wherein: a bottom wall of the housing comprises a bottom surface, andthe X-ray discernable indicia are recessed into the bottom surface of the bottom wall, whereby the X-ray discernable indicia are visible by an unaided eye prior to implantation of the port assembly.
15. The port assembly of claim 14, wherein the housing further comprises a generally planar portion of radiopaque material recessed into the bottom surface of the bottom wall, the generally planar portion of radiopaque material comprising one or more cutouts forming the X-ray discernable indicia that indicate the attribute of the port assembly.
16. The port assembly of claim 14, wherein the X-ray discernable indicia comprise one or more discrete elements of radiopaque material separately recessed into the bottom surface of the bottom wall, the one or more discrete elements indicating the attribute of the port assembly.
17. The port assembly of claim 13, wherein: the attribute of the port assembly is a pressure property of the port assembly, andthe X-ray discernable indicia indicate the pressure property of the port assembly.
18. The port assembly of claim 13, wherein the X-ray discernable indicia indicate that the port assembly is rated to be used for power injection.
19. The port assembly of claim 18, wherein the X-ray discernable indicia indicate that the port assembly is adapted to withstand high pressures used for injection of contrast fluid.
20. The port assembly of claim 13, wherein the X-ray discernable indicia are formed by titanium.
21. The port assembly of claim 13, wherein the X-ray discernable indicia are formed by silicone and a barium sulfate filler.
22. The port assembly of claim 13, wherein the housing further comprises a skirt formed from radiotransparent material molded around at least a portion of the housing.
23. The port assembly of claim 13, wherein the X-ray discernable indicia comprise one or more alphabetical letters.
24. The port assembly of claim 23, wherein the one or more alphabetical letters comprise the letters “C” and “T”.
25. An implantable venous access port assembly, comprising: a needle-penetrable septum;a housing having a bottom wall securing the needle-penetrable septum; andan X-ray discernable indicia comprising radiopaque material, wherein the X-ray discernable indicia identify an attribute of the access port assembly,wherein the X-ray discernable indicia are cut outs formed through at least a portion of the radiopaque material,wherein the X-ray discernable indicia are affixed to an outer surface the bottom wall.
26. The port assembly of claim 25, wherein the X-ray discernable indicia are centered within the region directly beneath the septum.
27. The port assembly of claim 25, wherein: the bottom wall comprises a bottom surface, andthe X-ray discernable indicia are recessed into the bottom surface of the bottom wall, whereby the X-ray discernable indicia are visible by an unaided eye prior to implantation of the port assembly.
28. The port assembly of claim 27, wherein the housing further comprises a generally planar portion of radiopaque material recessed into the bottom surface of the bottom wall, the generally planar portion of radiopaque material comprising one or more cutouts forming the X-ray discernable indicia that visually indicate, under X-ray examination, the attribute of the port assembly.
29. The port assembly of claim 27, wherein the X-ray discernable indicia comprise one or more discrete elements of radiopaque material separately recessed into the bottom surface of the bottom wall, the one or more discrete elements visually indicating, under X-ray examination, the attribute of the port assembly.
30. The port assembly of claim 25, wherein: the attribute of the port assembly is a pressure property of the port assembly, andthe X-ray discernable indicia visually indicate, under X-ray examination, the pressure property of the port assembly.
31. The port assembly of claim 30, wherein the X-ray discernable indicia visually indicate, under X-ray examination, that the port assembly is rated to be used for power injection.
32. The port assembly of claim 30, wherein the X-ray discernable indicia visually indicate, under X-ray examination, that the port assembly is adapted to withstand high pressures used for injection of contrast fluid.
33. The port assembly of claim 25, wherein the radiopaque material comprises titanium.
34. The port assembly of claim 25, wherein the radiopaque material comprises silicone and a barium sulfate filler.
35. The port assembly of claim 25, wherein the housing further comprises a skirt formed from radiotransparent material molded around at least a portion of a housing base of the housing.
36. The port assembly of claim 25, wherein the X-ray discernable indicia comprise one or more alphabetical letters.
37. The port assembly of claim 36, wherein the one or more alphabetical letters comprise the letters “C” and “T”.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 13/088,762, filed Apr. 18, 2011, which is a continuation of U.S. patent application Ser. No. 12/175,182, filed Jul. 17, 2008, which claims the benefit of U.S. Patent Application Ser. No. 60/961,133, filed Jul. 19, 2007, the contents of all said applications are incorporated herein by reference.

US Referenced Citations (542)

Number	Name	Date	Kind
574387	Buckler	Jan 1897	A
611357	Dembinski	Sep 1898	A
966696	Merrill	Aug 1910	A
1713267	Crowley	May 1929	A
2029553	Bartschi et al.	Feb 1936	A
2433480	Rendich	Dec 1947	A
2891689	Gould	Jun 1959	A
D198453	Weichselbaum	Jun 1964	S
3293663	Cronin	Dec 1966	A
3341417	Sinaiko	Sep 1967	A
3518428	Ring	Jun 1970	A
3529633	Vaillancourt	Sep 1970	A
3643358	Morderosian	Feb 1972	A
3829904	Ling et al.	Aug 1974	A
3831583	Edmunds, Jr. et al.	Aug 1974	A
3840009	Michaels et al.	Oct 1974	A
3891997	Herbert	Jul 1975	A
3915162	Miller	Oct 1975	A
3919724	Sanders et al.	Nov 1975	A
3922726	Trentani et al.	Dec 1975	A
3951147	Tucker et al.	Apr 1976	A
4027391	Samis et al.	Jun 1977	A
4035653	Karasko	Jul 1977	A
4121108	Manor	Oct 1978	A
4123806	Amstutz et al.	Nov 1978	A
4168586	Samis	Sep 1979	A
4181132	Parks	Jan 1980	A
4190040	Schulte	Feb 1980	A
4190057	Hill et al.	Feb 1980	A
4194122	Mitchell et al.	Mar 1980	A
4202349	Jones	May 1980	A
4222374	Sampson et al.	Sep 1980	A
4233964	Jefferts et al.	Nov 1980	A
4274006	Caine	Jun 1981	A
4349498	Ellis et al.	Sep 1982	A
4361153	Slocum et al.	Nov 1982	A
4405305	Stephen et al.	Sep 1983	A
4406567	Samis et al.	Sep 1983	A
4425119	Berglund	Jan 1984	A
4445896	Gianturco	May 1984	A
4450592	Niederer et al.	May 1984	A
4450985	Beard	May 1984	A
4456011	Warnecke et al.	Jun 1984	A
4469483	Becker et al.	Sep 1984	A
4494545	Slocum et al.	Jan 1985	A
4506676	Duska	Mar 1985	A
4529635	Sheldon	Jul 1985	A
4543088	Bootman et al.	Sep 1985	A
4549879	Groshong et al.	Oct 1985	A
4559046	Groshong et al.	Dec 1985	A
4560375	Schulte et al.	Dec 1985	A
4571749	Fischell	Feb 1986	A
4576595	Aas et al.	Mar 1986	A
4587954	Haber	May 1986	A
4612877	Hayes et al.	Sep 1986	A
4627844	Schmitt	Dec 1986	A
4634427	Hannula et al.	Jan 1987	A
4636194	Schulte et al.	Jan 1987	A
4636213	Pakiam	Jan 1987	A
4645495	Vaillancourt	Feb 1987	A
4653508	Cosman	Mar 1987	A
4655765	Swift	Apr 1987	A
4657024	Coneys	Apr 1987	A
4662652	Hargis	May 1987	A
4668221	Luther	May 1987	A
4671796	Groshong et al.	Jun 1987	A
4673394	Fenton, Jr. et al.	Jun 1987	A
4684365	Reinicke	Aug 1987	A
4685447	Iversen et al.	Aug 1987	A
4685905	Jeanneret nee Aab	Aug 1987	A
4692146	Hilger	Sep 1987	A
4695273	Brown	Sep 1987	A
4697595	Breyer et al.	Oct 1987	A
4701166	Groshong et al.	Oct 1987	A
4704103	Stoeber et al.	Nov 1987	A
4710174	Moden et al.	Dec 1987	A
4718894	Lazorthes	Jan 1988	A
4728894	Yoda et al.	Mar 1988	A
4743231	Kay et al.	May 1988	A
4753640	Nichols et al.	Jun 1988	A
4755173	Konopka et al.	Jul 1988	A
4760837	Petit	Aug 1988	A
4762517	McIntyre et al.	Aug 1988	A
4767410	Moden et al.	Aug 1988	A
4772270	Wiita et al.	Sep 1988	A
4772276	Wiita et al.	Sep 1988	A
4773552	Boege et al.	Sep 1988	A
4778452	Moden et al.	Oct 1988	A
4781680	Redmond et al.	Nov 1988	A
4781685	Lehmann et al.	Nov 1988	A
4781695	Dalton	Nov 1988	A
4802885	Weeks et al.	Feb 1989	A
4804054	Howson et al.	Feb 1989	A
4820273	Reinicke	Apr 1989	A
4822341	Colone	Apr 1989	A
4840615	Hancock et al.	Jun 1989	A
4848346	Crawford	Jul 1989	A
4857053	Dalton	Aug 1989	A
4861341	Woodburn	Aug 1989	A
4863470	Carter	Sep 1989	A
4886501	Johnston et al.	Dec 1989	A
4892518	Cupp et al.	Jan 1990	A
4904241	Bark	Feb 1990	A
4905709	Bieganski et al.	Mar 1990	A
4909250	Smith	Mar 1990	A
4915690	Cone et al.	Apr 1990	A
4928298	Tanaka et al.	May 1990	A
4929236	Sampson	May 1990	A
4955861	Enegren et al.	Sep 1990	A
4963133	Whipple	Oct 1990	A
4966583	Debbas	Oct 1990	A
4973319	Melsky	Nov 1990	A
4983162	Metals et al.	Jan 1991	A
5009644	McDonald	Apr 1991	A
5013298	Moden et al.	May 1991	A
5041098	Loiterman et al.	Aug 1991	A
5044955	Jagmin	Sep 1991	A
5045060	Melsky et al.	Sep 1991	A
5045064	Idriss	Sep 1991	A
5084015	Moriuchi	Jan 1992	A
5085216	Henley, Jr. et al.	Feb 1992	A
5090066	Schoepe et al.	Feb 1992	A
5092849	Sampson	Mar 1992	A
5108317	Beinhaur et al.	Apr 1992	A
5108377	Cone et al.	Apr 1992	A
5112301	Fenton, Jr. et al.	May 1992	A
5112303	Pudenz et al.	May 1992	A
5129891	Young	Jul 1992	A
5137529	Watson et al.	Aug 1992	A
5147483	Melsky et al.	Sep 1992	A
5152753	Laguette et al.	Oct 1992	A
5156600	Young	Oct 1992	A
5158547	Doan et al.	Oct 1992	A
5167629	Vertenstein et al.	Dec 1992	A
5167633	Mann et al.	Dec 1992	A
5167638	Felix et al.	Dec 1992	A
5171228	McDonald	Dec 1992	A
5176653	Metals et al.	Jan 1993	A
5176662	Bartholomew et al.	Jan 1993	A
5178612	Fenton, Jr.	Jan 1993	A
5185003	Brethauer	Feb 1993	A
5189690	Samuel	Feb 1993	A
5193106	DeSena	Mar 1993	A
5195122	Fabian	Mar 1993	A
5195123	Clement	Mar 1993	A
5201715	Masters	Apr 1993	A
5203771	Melker et al.	Apr 1993	A
5203777	Lee	Apr 1993	A
5213574	Tucker	May 1993	A
5215537	Lynn et al.	Jun 1993	A
5222499	Allen et al.	Jun 1993	A
D337637	Tucker	Jul 1993	S
5224938	Fenton, Jr.	Jul 1993	A
5263930	Ensminger	Nov 1993	A
5281205	McPherson	Jan 1994	A
5290263	Wigness et al.	Mar 1994	A
5295658	Atkinson et al.	Mar 1994	A
5299253	Wessels	Mar 1994	A
5309863	Leeb, Jr.	May 1994	A
5312337	Flaherty et al.	May 1994	A
5318545	Tucker	Jun 1994	A
5320100	Herweck et al.	Jun 1994	A
5322511	Armbruster et al.	Jun 1994	A
5328480	Melker et al.	Jul 1994	A
5332398	Miller et al.	Jul 1994	A
5334153	McIntyre et al.	Aug 1994	A
5336194	Polaschegg et al.	Aug 1994	A
5338398	Szwejkowski et al.	Aug 1994	A
5350360	Ensminger et al.	Sep 1994	A
5352204	Ensminger	Oct 1994	A
5360407	Leonard	Nov 1994	A
5383233	Russell	Jan 1995	A
5383858	Reilly et al.	Jan 1995	A
D355240	Gladfelter et al.	Feb 1995	S
5387192	Glantz et al.	Feb 1995	A
5394457	Leibinger et al.	Feb 1995	A
5395324	Hinrichs et al.	Mar 1995	A
5397329	Allen	Mar 1995	A
5399168	Wadsworth, Jr. et al.	Mar 1995	A
5405402	Dye et al.	Apr 1995	A
5417565	Long	May 1995	A
5417656	Ensminger et al.	May 1995	A
5421814	Geary	Jun 1995	A
5423334	Jordan	Jun 1995	A
5425762	Muller	Jun 1995	A
5433480	Gresham et al.	Jul 1995	A
5456698	Byland et al.	Oct 1995	A
5476460	Montalvo	Dec 1995	A
5476880	Cooke et al.	Dec 1995	A
5484402	Saravia et al.	Jan 1996	A
5503630	Ensminger et al.	Apr 1996	A
5507813	Dowd et al.	Apr 1996	A
5509805	Jagmin	Apr 1996	A
5513637	Twiss et al.	May 1996	A
5514103	Srisathapat et al.	May 1996	A
5520632	Leveen et al.	May 1996	A
5527277	Ensminger et al.	Jun 1996	A
5527307	Srisathapat et al.	Jun 1996	A
5531684	Ensminger et al.	Jul 1996	A
5556381	Ensminger et al.	Sep 1996	A
5558641	Glantz et al.	Sep 1996	A
5562617	Finch, Jr. et al.	Oct 1996	A
5562618	Cai et al.	Oct 1996	A
5575770	Melsky et al.	Nov 1996	A
5607393	Ensminger et al.	Mar 1997	A
5607407	Tolkoff et al.	Mar 1997	A
5613945	Cai et al.	Mar 1997	A
5620419	Lui et al.	Apr 1997	A
5632729	Cai et al.	May 1997	A
5637102	Tolkoff et al.	Jun 1997	A
5638832	Singer et al.	Jun 1997	A
5647855	Trooskin	Jul 1997	A
5662600	Watson et al.	Sep 1997	A
5662612	Niehoff	Sep 1997	A
5676146	Scarborough	Oct 1997	A
5695490	Flaherty et al.	Dec 1997	A
5702128	Maxim et al.	Dec 1997	A
5702363	Flaherty	Dec 1997	A
5704915	Melsky et al.	Jan 1998	A
5709668	Wacks	Jan 1998	A
5713844	Peyman	Feb 1998	A
5713858	Heruth et al.	Feb 1998	A
5713859	Finch, Jr. et al.	Feb 1998	A
5718382	Jaeger	Feb 1998	A
5718682	Tucker	Feb 1998	A
5725507	Petrick	Mar 1998	A
5733336	Neuenfeldt et al.	Mar 1998	A
5733400	Gore et al.	Mar 1998	A
5741228	Lambrecht et al.	Apr 1998	A
5743873	Cai et al.	Apr 1998	A
5743891	Tolkoff et al.	Apr 1998	A
5746460	Marohl et al.	May 1998	A
5758667	Slettenmark	Jun 1998	A
5769823	Otto	Jun 1998	A
5773552	Hutchings et al.	Jun 1998	A
5776188	Shepherd et al.	Jul 1998	A
5792104	Speckman et al.	Aug 1998	A
5792116	Berg et al.	Aug 1998	A
5810789	Powers et al.	Sep 1998	A
5824071	Nelson et al.	Oct 1998	A
5830172	Leveen et al.	Nov 1998	A
5833654	Powers et al.	Nov 1998	A
5835563	Navab et al.	Nov 1998	A
5836935	Ashton et al.	Nov 1998	A
5840063	Flaherty	Nov 1998	A
5843069	Butler et al.	Dec 1998	A
5853394	Tolkoff et al.	Dec 1998	A
5868702	Stevens et al.	Feb 1999	A
5882353	VanBeek et al.	Mar 1999	A
5895424	Steele, Sr. et al.	Apr 1999	A
5906596	Tallarida	May 1999	A
5908414	Otto et al.	Jun 1999	A
5913998	Butler et al.	Jun 1999	A
5916263	Goicoechea et al.	Jun 1999	A
5925017	Kriesel et al.	Jul 1999	A
5925030	Gross et al.	Jul 1999	A
5928197	Niehoff	Jul 1999	A
5931829	Burbank et al.	Aug 1999	A
5935084	Southworth	Aug 1999	A
5944023	Johnson et al.	Aug 1999	A
5944688	Lois	Aug 1999	A
5944712	Frassica et al.	Aug 1999	A
5947953	Ash et al.	Sep 1999	A
5951512	Dalton	Sep 1999	A
5951522	Rosato et al.	Sep 1999	A
5954687	Baudino	Sep 1999	A
5957890	Mann et al.	Sep 1999	A
5968011	Larsen et al.	Oct 1999	A
5970162	Kawashima et al.	Oct 1999	A
5989216	Johnson et al.	Nov 1999	A
5989239	Finch et al.	Nov 1999	A
5997524	Burbank et al.	Dec 1999	A
6007516	Burbank et al.	Dec 1999	A
6013051	Nelson	Jan 2000	A
6013058	Prosl et al.	Jan 2000	A
6017331	Watts et al.	Jan 2000	A
6022335	Ramadan	Feb 2000	A
6033389	Cornish	Mar 2000	A
6039712	Fogarty et al.	Mar 2000	A
6077756	Lin et al.	Jun 2000	A
6086555	Eliasen	Jul 2000	A
6090066	Schnell	Jul 2000	A
6102884	Squitieri	Aug 2000	A
6113572	Gailey et al.	Sep 2000	A
6120492	Finch et al.	Sep 2000	A
6161033	Kuhn	Dec 2000	A
6171198	Lizama Troncoso et al.	Jan 2001	B1
6171298	Matsuura et al.	Jan 2001	B1
6174330	Stinson	Jan 2001	B1
6190352	Haarala et al.	Feb 2001	B1
6193684	Burbank et al.	Feb 2001	B1
6198807	DeSena	Mar 2001	B1
6203570	Baeke	Mar 2001	B1
6213973	Eliasen et al.	Apr 2001	B1
6228088	Miller et al.	May 2001	B1
6251059	Apple et al.	Jun 2001	B1
D445175	Bertheas	Jul 2001	S
6269148	Jessop et al.	Jul 2001	B1
6287293	Jones et al.	Sep 2001	B1
6290677	Arai et al.	Sep 2001	B1
6302875	Makower et al.	Oct 2001	B1
6305413	Fischer et al.	Oct 2001	B1
D450115	Bertheas	Nov 2001	S
6332874	Eliasen et al.	Dec 2001	B1
6347241	Burbank et al.	Feb 2002	B2
6355021	Nielsen et al.	Mar 2002	B1
6356782	Sirimanne et al.	Mar 2002	B1
6361557	Gittings et al.	Mar 2002	B1
6398764	Finch, Jr. et al.	Jun 2002	B1
6419680	Cosman et al.	Jul 2002	B1
6450937	Mercereau et al.	Sep 2002	B1
6459772	Wiedenhoefer et al.	Oct 2002	B1
6478783	Moorehead	Nov 2002	B1
6482217	Pintor et al.	Nov 2002	B1
6494867	Elver et al.	Dec 2002	B1
6497062	Koopman et al.	Dec 2002	B1
6500155	Sasso	Dec 2002	B2
6503228	Li et al.	Jan 2003	B1
6527754	Tallarida et al.	Mar 2003	B1
6537255	Raines	Mar 2003	B1
RE38074	Recinella et al.	Apr 2003	E
6582418	Verbeek et al.	Jun 2003	B1
6613002	Clark et al.	Sep 2003	B1
6613662	Wark et al.	Sep 2003	B2
6626936	Stinson	Sep 2003	B2
6629950	Levin	Oct 2003	B1
6632217	Harper et al.	Oct 2003	B2
6652486	Bialecki et al.	Nov 2003	B2
6652503	Bradley	Nov 2003	B1
6676633	Smith et al.	Jan 2004	B2
6697664	Kienzle, III et al.	Feb 2004	B2
6705316	Blythe et al.	Mar 2004	B2
6719721	Okazaki et al.	Apr 2004	B1
6719739	Verbeek et al.	Apr 2004	B2
6738531	Funahashi	May 2004	B1
6755842	Kanner et al.	Jun 2004	B2
6758841	Haarala et al.	Jul 2004	B2
6767356	Kanner et al.	Jul 2004	B2
6784783	Scoggin et al.	Aug 2004	B2
6826257	Sayre et al.	Nov 2004	B2
6852106	Watson et al.	Feb 2005	B2
6878136	Fleury et al.	Apr 2005	B2
6878137	Benchetrit	Apr 2005	B2
6949084	Marggi et al.	Sep 2005	B2
6962580	Adams et al.	Nov 2005	B2
6994315	Ryan et al.	Feb 2006	B2
6997914	Smith et al.	Feb 2006	B2
7008377	Beane et al.	Mar 2006	B2
7008412	Maginot	Mar 2006	B2
7016456	Basu et al.	Mar 2006	B2
7018361	Gillespie, Jr. et al.	Mar 2006	B2
7044942	Jolly et al.	May 2006	B2
7056316	Burbank et al.	Jun 2006	B1
7070591	Adams et al.	Jul 2006	B2
7072704	Bucholz	Jul 2006	B2
7074232	Kanner et al.	Jul 2006	B2
7083593	Stultz	Aug 2006	B2
7108686	Burke et al.	Sep 2006	B2
7123690	Brown et al.	Oct 2006	B1
7127040	Sayre et al.	Oct 2006	B2
7131962	Estabrook et al.	Nov 2006	B1
7140769	Kay	Nov 2006	B2
7191011	Cantlon	Mar 2007	B2
7198631	Kanner et al.	Apr 2007	B2
7214207	Lynch et al.	May 2007	B2
7214215	Heinzerling et al.	May 2007	B2
7223257	Shubayev et al.	May 2007	B2
7229417	Foerster et al.	Jun 2007	B2
7235067	Morris et al.	Jun 2007	B2
D546440	Burnside	Jul 2007	S
7242982	Singhal et al.	Jul 2007	B2
7252469	Zaluzec et al.	Aug 2007	B2
7252649	Sherry	Aug 2007	B2
7261705	Edoga et al.	Aug 2007	B2
D554253	Kornerup	Oct 2007	S
7275682	Excoffier et al.	Oct 2007	B2
7276075	Callas et al.	Oct 2007	B1
D556153	Burnside	Nov 2007	S
7306579	Fujii	Dec 2007	B2
7311702	Tallarida et al.	Dec 2007	B2
7318816	Bobroff et al.	Jan 2008	B2
7318818	Yashiro et al.	Jan 2008	B2
7322953	Redinger	Jan 2008	B2
D562443	Zinn et al.	Feb 2008	S
7331130	Shweikert	Feb 2008	B2
7331948	Skarda	Feb 2008	B2
7333013	Berger	Feb 2008	B2
D564449	Dewberry	Mar 2008	S
7347838	Kulli	Mar 2008	B2
7347843	Adams et al.	Mar 2008	B2
7351233	Parks	Apr 2008	B2
7377915	Rasmussen et al.	May 2008	B2
D574950	Zawacki et al.	Aug 2008	S
7413564	Morris et al.	Aug 2008	B2
D578203	Bizup	Oct 2008	S
7445614	Bunodiere et al.	Nov 2008	B2
D582032	Bizup et al.	Dec 2008	S
7465847	Fabian	Dec 2008	B2
D595892	Smith et al.	Jul 2009	S
7563025	Kay	Jul 2009	B2
D612479	Zawacki et al.	Mar 2010	S
7713251	Tallarida et al.	May 2010	B2
7785302	Powers	Aug 2010	B2
7833281	Lehman et al.	Nov 2010	B2
8021324	Bizup et al.	Sep 2011	B2
8257325	Schweikert et al.	Sep 2012	B2
9517329	Bizup et al.	Dec 2016	B2
10052470	Powers et al.	Aug 2018	B2
10179230	Powers et al.	Jan 2019	B2
10183157	Powers et al.	Jan 2019	B2
10625065	Powers et al.	Apr 2020	B2
20010016717	Haarala et al.	Aug 2001	A1
20010051766	Gazdzinski	Dec 2001	A1
20010053889	Marggi et al.	Dec 2001	A1
20010056266	Tallarida et al.	Dec 2001	A1
20020095205	Edwin et al.	Jul 2002	A1
20020138068	Watson et al.	Sep 2002	A1
20020173769	Gray et al.	Nov 2002	A1
20030010929	Priewe et al.	Jan 2003	A1
20030028173	Forsberg	Feb 2003	A1
20030130627	Smith	Jul 2003	A1
20030139812	Garcia et al.	Jul 2003	A1
20030181878	Tallarida et al.	Sep 2003	A1
20030191452	Meglin et al.	Oct 2003	A1
20040002693	Bright et al.	Jan 2004	A1
20040006316	Patton	Jan 2004	A1
20040019356	Fraser et al.	Jan 2004	A1
20040020462	Sauler et al.	Feb 2004	A1
20040044306	Lynch et al.	Mar 2004	A1
20040054352	Adams et al.	Mar 2004	A1
20040056266	Suh et al.	Mar 2004	A1
20040064110	Forsell	Apr 2004	A1
20040073196	Adams et al.	Apr 2004	A1
20040093069	Priewe et al.	May 2004	A1
20040106878	Skujins et al.	Jun 2004	A1
20040106891	Langan et al.	Jun 2004	A1
20040157952	Soffiati et al.	Aug 2004	A1
20040158207	Hunn et al.	Aug 2004	A1
20040167543	Mazzocchi et al.	Aug 2004	A1
20040176743	Morris et al.	Sep 2004	A1
20040199129	DiMatteo	Oct 2004	A1
20040199220	Cantlon	Oct 2004	A1
20040204692	Eliasen	Oct 2004	A1
20040225254	Tanaka et al.	Nov 2004	A1
20040254536	Conlon et al.	Dec 2004	A1
20040254537	Conlon et al.	Dec 2004	A1
20050049553	Triplett et al.	Mar 2005	A1
20050070875	Kulessa	Mar 2005	A1
20050075614	Bunodiere et al.	Apr 2005	A1
20050113806	De Carvalho et al.	May 2005	A1
20050131352	Conlon et al.	Jun 2005	A1
20050148866	Gunderson	Jul 2005	A1
20050148956	Conlon et al.	Jul 2005	A1
20050148957	Girard et al.	Jul 2005	A1
20050152841	Sayre et al.	Jul 2005	A1
20050171502	Daly et al.	Aug 2005	A1
20050182857	Kong	Aug 2005	A1
20050209573	Brugger et al.	Sep 2005	A1
20050215874	Wang et al.	Sep 2005	A1
20050215876	Chen et al.	Sep 2005	A1
20050241203	Lizotte et al.	Nov 2005	A1
20050256451	Adams et al.	Nov 2005	A1
20050256500	Fujii	Nov 2005	A1
20050277899	Conlon et al.	Dec 2005	A1
20050283119	Uth et al.	Dec 2005	A1
20060009788	Freeman et al.	Jan 2006	A1
20060017341	Hahn et al.	Jan 2006	A1
20060084929	Eliasen	Apr 2006	A1
20060089619	Ginggen	Apr 2006	A1
20060100592	Eliasen	May 2006	A1
20060116648	Hamatake	Jun 2006	A1
20060173410	Moberg et al.	Aug 2006	A1
20060173424	Conlon	Aug 2006	A1
20060178647	Stats	Aug 2006	A1
20060184141	Smith et al.	Aug 2006	A1
20060184142	Schon et al.	Aug 2006	A1
20060217359	Wentworth et al.	Sep 2006	A1
20060217659	Patton	Sep 2006	A1
20060224128	Lurvey et al.	Oct 2006	A1
20060224129	Beasley et al.	Oct 2006	A1
20060247584	Sheetz et al.	Nov 2006	A1
20060253076	Butts et al.	Nov 2006	A1
20060264898	Beasley et al.	Nov 2006	A1
20070007839	Lin	Jan 2007	A1
20070049876	Patton	Mar 2007	A1
20070055290	Lober	Mar 2007	A1
20070073250	Schneiter	Mar 2007	A1
20070078391	Wortley et al.	Apr 2007	A1
20070078416	Eliasen	Apr 2007	A1
20070078432	Halseth et al.	Apr 2007	A1
20070083156	Muto et al.	Apr 2007	A1
20070149920	Michels et al.	Jun 2007	A1
20070149921	Michels et al.	Jun 2007	A1
20070161958	Glenn	Jul 2007	A1
20070161985	Demakas et al.	Jul 2007	A1
20070179456	Glenn	Aug 2007	A1
20070185462	Byrum	Aug 2007	A1
20070191773	Wojcik	Aug 2007	A1
20070208313	Conlon et al.	Sep 2007	A1
20070219510	Zinn et al.	Sep 2007	A1
20070233017	Zinn et al.	Oct 2007	A1
20070233018	Bizup et al.	Oct 2007	A1
20070255234	Haase et al.	Nov 2007	A1
20070270691	Bailey et al.	Nov 2007	A1
20070270770	Bizup	Nov 2007	A1
20070276344	Bizup et al.	Nov 2007	A1
20070299408	Alferness et al.	Dec 2007	A1
20080004642	Birk et al.	Jan 2008	A1
20080008654	Clarke et al.	Jan 2008	A1
20080015701	Garcia et al.	Jan 2008	A1
20080039820	Sommers et al.	Feb 2008	A1
20080048855	Berger	Feb 2008	A1
20080108949	Beasley et al.	May 2008	A1
20080114308	di Palma et al.	May 2008	A1
20080138387	Machiraju	Jun 2008	A1
20080140025	Sheetz et al.	Jun 2008	A1
20080208236	Hobbs et al.	Aug 2008	A1
20080281279	Hoendervoogt et al.	Nov 2008	A1
20080319398	Bizup	Dec 2008	A1
20080319399	Schweikert et al.	Dec 2008	A1
20080319405	Bizup	Dec 2008	A1
20090024024	Zinn	Jan 2009	A1
20090024098	Bizup et al.	Jan 2009	A1
20090035582	Nakatani et al.	Feb 2009	A1
20090118683	Hanson et al.	May 2009	A1
20090156928	Evans et al.	Jun 2009	A1
20090171436	Casanova et al.	Jul 2009	A1
20090199857	Peake et al.	Aug 2009	A1
20090204072	Amin et al.	Aug 2009	A1
20090204074	Powers et al.	Aug 2009	A1
20090221976	Linden	Sep 2009	A1
20090227862	Smith et al.	Sep 2009	A1
20090227951	Powers et al.	Sep 2009	A1
20100004735	Yang et al.	Jan 2010	A1
20100042073	Oster et al.	Feb 2010	A1
20100069743	Sheetz et al.	Mar 2010	A1
20190134373	Barron et al.	May 2019	A1
20190151641	Powers et al.	May 2019	A1
20190217073	Maniar et al.	Jul 2019	A1
20190252603	Wiley et al.	Aug 2019	A1
20190275311	Hibdon et al.	Sep 2019	A1
20200086105	Powers et al.	Mar 2020	A1

Foreign Referenced Citations (69)

Number	Date	Country
2693972	Jan 2009	CA
84 37 873	Feb 1986	DE
34 47 202	Jul 1986	DE
197 45 654	Apr 1999	DE
0619101	Oct 1994	EP
0 750 520	Aug 2000	EP
1238682	Sep 2002	EP
2180915	May 2010	EP
1896117	Jan 2011	EP
3311877	Apr 2018	EP
1509165	Jan 1968	FR
2 569 987	Mar 1986	FR
2 586 569	Mar 1987	FR
2 203 342	Oct 1988	GB
2500388	Jun 1996	JP
08-168322	Jul 1996	JP
2602109	Apr 1997	JP
2003-102831	Apr 2003	JP
2004-350937	Dec 2004	JP
2006-500087	Jan 2006	JP
2006-025948	Feb 2006	JP
2010000703	Jul 2010	MX
WO-198600213	Jan 1986	WO
WO-199305730	Apr 1993	WO
WO-1995014504	Jun 1995	WO
WO-199701370	Jan 1997	WO
WO-1997006845	Feb 1997	WO
WO-1997011726	Apr 1997	WO
WO-1998017337	Apr 1998	WO
WO-199942166	Aug 1999	WO
WO-200033901	Jun 2000	WO
WO-2000047264	Aug 2000	WO
WO-200247549	Jun 2002	WO
WO-2002100480	Dec 2002	WO
WO-2003037215	May 2003	WO
WO-2003086508	Oct 2003	WO
WO-2004004800	Jan 2004	WO
WO-2004071555	Aug 2004	WO
WO-2004091434	Oct 2004	WO
WO-2005037055	Apr 2005	WO
WO-2006078915	Jul 2006	WO
2006096686	Sep 2006	WO
WO-2006096686	Sep 2006	WO
2006116438	Nov 2006	WO
WO-2006116438	Nov 2006	WO
WO-2006130133	Dec 2006	WO
WO-2006134100	Dec 2006	WO
WO-2007079024	Jul 2007	WO
WO-2007092210	Aug 2007	WO
WO-2007094898	Aug 2007	WO
WO-2007098771	Sep 2007	WO
WO-2007109164	Sep 2007	WO
WO-2007126645	Nov 2007	WO
WO-2007136538	Nov 2007	WO
WO-2008008126	Jan 2008	WO
WO-2008019236	Feb 2008	WO
2008048361	Apr 2008	WO
WO-2008048361	Apr 2008	WO
WO-2008063226	May 2008	WO
2008157763	Dec 2008	WO
WO-2008147760	Dec 2008	WO
WO-2008157763	Dec 2008	WO
WO-2009002839	Dec 2008	WO
2009012385	Jan 2009	WO
WO-2009012395	Jan 2009	WO
WO-2009035582	Mar 2009	WO
WO-2009046439	Apr 2009	WO
WO-2009046725	Apr 2009	WO
WO-2009108669	Sep 2009	WO

Non-Patent Literature Citations (190)

Entry
BARD Access System product drawings representative of the BARD Access System products on the market on or around Mar. 1995 as indicated by the BARD Access Systems Mar. 21, 1995 Product Release to Market form for “M.R.I. Port with 8 Fr. ChronoFlex Catheter,” “M.R.I. Port with 8 Fr. ChronoFlex Catheter with Intro-Eze,” “M.R.I. Port with 8 Fr. Chromo-Flex Catheter and Peel Apart,” “M.R.I. Port with 8 Fr. ChronoFlex Catheter Demo Kit,” 6 pages.
Bard Access Systems, Inc. “Hickman Subcutaneous Ports & Hickman/Broviac Catheters,” Bard Exhibit 1017, p. 1-5, 1992, Bard Access Systems.
Bard Access Systems, Inc. “Power Port—Implantable Port—Feel the New Standard of Care—Guidelines for CT Technologists,” Bard Exhibit 1004, p. 1, Feb. 2007, C.R. Bard, Inc.
Bard Access Systems, Inc., Extreme Access, “PORTS—Setting the Standard with a Comprehensive Family of Ports,” Bard Exhibit 1002, p. 1-17, 2003 Bard Access Systems.
Biffi, R. et al. “Best Choice of Central Venous Insertion Site for the Prevention of Catheter-Related Complications in Adult Patients Who Need Cancer Therapy: A Randomized Trial.” Annals of Oncology, Jan. 29, 2009, 6 pages.
Biffi, R. et al. “Use of totally implantable central venous access ports for high-dose chemotherapy and peripheral blood stem cell transplantation: results of a monocentre series of 376 patients.” Annals of Oncology 15:296-300, 2004, 5 pages.
Biffi, Roberto, et al. “A Randomized, Prospective Trial of Central Venous Ports Connected to Standard Open-Ended or Groshong Catheters in Adult Oncology Patients.” American Cancer Society, vol. 92, No. 5, pp. 1204-1212, Sep. 1, 2001, 9 pages.
BioEnterics® LAP-BAND® “Adjustable Gastric Banding System” by Inamed Health, Product Brochure, Dec. 2003, 22 pages.
Cardiovascular and Interventional Radiology, Review Article, “Central Venous Access Catheters: Radiological Management of Complications,” by U.K. Teichgraber et al., published online Jul. 31, 2003, 13 pages.
Costa, Nancy, “Understanding Contrast Media.” Journal of Infusion Nursing, vol. 27, No. 5, Sep./Oct. 2004, 11 pages.
Costa, Nancy, “More Than Skin Deep: An Overview of Iodinated Contrast Media.” Journal for the Association for Vascular Access, vol. 8, No. 4, 2003, 6 pages.
European Patent Office Communication, dated Dec. 15, 2005, for Application No. 99 964 086.5-1257, Applicant STD Manufacturing, Inc., 9 pages.
European Patent Office Communication, dated Mar. 1, 2005, for EP Application No. 99 964 086.5-1257, Applicant STD Manufacturing, Inc., 4 pages.
European Patent Office Communication, dated Mar. 30, 2005, for Application No. 99 964 086.5-1257, Applicant STD Manufacturing, Inc., 3 pages.
European Patent Office Communication, dated Sep. 2, 2008, for Application No. 06 751 411.7-1526, Applicant C.R. Bard, Inc., 4 pages.
“Extravasation of Radiologic Contrast.” PA-PSRS Patient Safety Advisory—vol. 1, No. 3, Sep. 2004, 6 pages.
Extreme Access, Bard Access Systems, Inc., Product Brochure, 2003, 5 pages.
Fallscheer, et al., “Injury to the Upper Extremity Caused by Extravasation of Contrast Medium: A True Emergency.” Scandinavian Journal of Plastic and Reconstructive Surgery and Hand Surgery, vol. 41, pp. 26-32, 2007, 7 pages.
Hou, Shaw-Min et al. “Comparisons of Outcomes and Survivals for Two Central Venous Access Port Systems.” Journal of Surgical Oncology, 91:61-66, 2005, 6 pages.
http: /web. archive.org/web/20001119035900/www.deltec.com/cPacspl.htm, last accessed Oct. 17, 2009, 2 pages.
http://www. cochlearamericas. com/PDFs/UserManualSprint.pdf, Issue 2, Dec. 2001, 2 pages.
International Application No. PCT/US1999/028695, International Search Report, dated Apr. 11, 2000, 2 pages.
International Application No. PCT/US1999/028695, International Preliminary Examination Report, dated Apr. 21, 2001, 4 pages.
International Application No. PCT/US2006/008022, International Preliminary Report on Patentability and Written Opinion, dated Sep. 12, 2007, 6 pages.
International Application No. PCT/US2006/008022, International Search Report, dated Jul. 5, 2006, 2 pages.
International Application No. PCT/US2006/015695, International Search Report, dated Jan. 11, 2007, 6 pages.
International Application No. PCT/US2006/015695, Written Opinion, dated Oct. 30, 2007, 8 pages.
International Application No. PCT/US2006/016056, International Search Report, dated Sep. 20, 2006, 4 pages.
International Application No. PCT/US2006/016056, International Preliminary Report on Patentability and Written Opinion, dated Oct. 30, 2007, 9 pages.
International Application No. PCT/US2006/049007, International Preliminary Report on Patentability and Written Opinion, dated Jul. 1, 2008, 5 pages.
International Application No. PCT/US2006/49007, International Search Report, dated Oct. 1, 2007, 2 pages.
International Application No. PCT/US2006/49007, Written Opinion, dated Oct. 1, 2007, 4 pages.
International Application No. PCT/US2007/006776, International Preliminary Report on Patentability, dated Nov. 16, 2008, 3 pages.
International Application No. PCT/US2007/006776, International Search Report, dated Dec. 18, 2007, 1 page.
International Application No. PCT/US2007/006776, Written Opinion, dated Dec. 18, 2007, 3 pages.
International Application No. PCT/US2007/011015, International Search Report, dated Jun. 10, 2008, 2 pages.
International Application No. PCT/US2007/011015, International Preliminary Report on Patentability, dated Nov. 23, 2009, 9 pages.
International Application No. PCT/US2007/011015, Written Opinion, dated Jun. 10, 2008, 3 pages.
International Application No. PCT/US2007/011456, International Search Report, dated Aug. 28, 2008, 2 pages.
International Application No. PCT/US2007/011456, Written Opinion, dated Aug. 28, 2008, 4 pages.
International Application No. PCT/US2008/010520, International Search Report, dated Feb. 24, 2009, 2 pages.
International Application No. PCT/US2008/010520, Written Opinion, dated Feb. 24, 2009, 4 pages.
International Application No. PCT/US2008/067679, International Search Report, dated Sep. 30, 2008, 3 pages.
International Application No. PCT/US2008/067679, Written Opinion, dated Sep. 30, 2008, 4 pages.
International Application No. PCT/US2008/070330, International Search Report, dated Dec. 1, 2008, 5 pages.
International Application No. PCT/US2008/070330, Written Opinion, dated Dec. 1, 2008, 5 pages.
International Application No. PCT/US2008/070345, International Search Report, dated Dec. 1, 2008, 5 pages.
International Application No. PCT/US2008/070345, Written Opinion, dated Dec. 1, 2008, 6 pages.
International Application No. PCT/US2008/078976, International Search Report and Written Opinion, dated Apr. 3, 2009, 6 pages.
International Application No. PCT/US2009/062854, International Search Report, dated Dec. 23, 2009, 2 pages.
Johnson, Kathleen A., “Power Injectable Portal Systems,” Journal of Radiology Nursing, vol. 28, Issue 1, Mar., 2009, 6 pages.
LaMaitre Vascular “Port Implantations: using the OptiLock Implantable Port,” product information, available at http://www.lemaitre. com/specs_pop.asp, last accessed Apr. 2003, 14 pages.
LAP-BAND AP™ “System with Adjustable Gastric Banding system with OMNIFORM™ Design,” Product Brochure, Jul. 2007, 16 pages.
LAP-BAND System Access Port Fill Guide I, “9.75/10.0 cm LAP-BAND System vs. 11 cm LAP-BAND System: For Product Manufactured Prior to Jul. 2001” BioEnterics Corporation, 1 page.
LAP-BAND® “Adjustable Gastric Banding System” by BioEnterics Corporation, Product Brochure, 12 pages.
LAP-BAND® System Fact Sheet, © 2007 Allergan, Inc., 2 pages.
MedComp “PortCT Technology”, display at SIR Conference, Toronto, Canada, (Mar. 2006), 1 page.
Nucleus Cochlear Implant Systems; User Manual for the ESPrit 3G speech processor and accessories, available at http://www.choclearamericas.com/PDFs/UserManualSprint.pdf, Issue 2, Dec. 2001, 2 pages.
Oct. 22, 2009 Declaration of Kelly Christian, Director of Product Development at BARD Access Systems, Inc, in support of and depicting a product on the market by Quinton Company approximately ten years prior to Oct. 22, 2009, 1 page.
Plinski, et al., “Implantable Cardioverter-Defribillators: Implications for the Nonelectrophysiologist,” Annals of Internal Medicine, Abstract of vol. 122 No. 10, pp. 770-777, May 15, 1995, 3 pages.
Port-A-Cath P.A.S. PORT Systems by Deltec, Product Specifications, 1999, 2 pages.
PORT-A-CATH® “Implantable Epidural, Aterial and Peritonial Access Systems,” Internet Product Listing of Nov. 19, 2000 archived at.
PORT-A-CATH® “Many PORT-A-CATH® System Choices,” Product Brochure, © 1996 SIMS Deltec, Inc., 5 pages.
PORT-A-CATH® “Single-lumen Implantable Vascular Access Systems,” Product Specifications, 2004 Smith Medical, 4 pages.
Rappolt, Richard T., et al., “Radiopaque Codification and X-ray identification of Ingested Drugs,” Ingestive Radiology, May-Jun. 1966, 4 pages.
Sandstede, Joern, “Pediatric CT,” available online at www.multislice- ct.com, MultiSLICE-CT.com, version 02, May 2, 2003, 36 pages.
Sanelli, et al., “Safety and Feasibility of Using a Central Venous Catheter for Rapid Contrast Injection Rates.” American Journal of Radiology, vol. 183, pp. 1829-1834, Dec. 2004, 6 pages.
Shah, Tilak M. “Radiopaque Polymer Formulations for Medical Devices.” Medical Device and Diagnostic Industry, Mar. 2000, 6 pages.
Smith, Lisa Hartkoph, “Implanted Ports, Computer Tomography, Power Injectors, and Catheter Rupture.” Clinical Journal of Oncology Nursing, vol. 12, No. 5 Oct. 2008, 4 pages.
Solomon, et al., “CIN Strategies: Anticipate, Manage, Prevent.” Supplement to Imaging Economics, May 2007, 20 pages.
Steinbach, Barbara, G., Hardt, N. Sisson, Abbitt, Patricia L., Lanier, Linda, Caffee, H. Hollis, “Breast Implants, Common Complications, and Concurrent Breast Disease.” RadioGraphics, vol. 13, No. 1, pp. 95-118, 1993, 24 pages.
Sullivan et al. “Radiopaque Markers on Mammary Implants.” American Journal of Roentgenology 153(2):428, Aug. 1989, 2 pages.
Thistlethwaite et al., “Generalized Feature-Based RSA of Orthopaedic Implants,” 2003 Summer Bioengineering Conference, Jun. 25-29, Sonesta Beach Resort in Key Biscayne, Florida, 2 pages.
U.S. Appl. No. 10/374,000, Advisory Action, dated Jan. 23, 2007, 3 pages.
U.S. Appl. No. 10/374,000, Office Action, dated Sep. 30, 2008, 7 pages.
U.S. Appl. No. 10/374,000, Response to Office Action, filed Dec. 28, 2006, 9 pages.
U.S. Appl. No. 10/374,000, Response to Office Action, filed Oct. 31, 2007, 8 pages.
U.S. Appl. No. 11/320,223, Office Action, dated Sep. 18, 2008, 7 pages.
U.S. Appl. No. 11/725,287, Notice of Withdrawal from Issue, dated Oct. 23, 2009, 1 page.
U.S. Appl. No. 11/725,287, Supplemental Response and Suggestion of Interference, filed Feb. 18, 2011, 64 pages.
U.S. Appl. No. 11/725,287, Supplemental Response and Suggestion of Interference, filed May 26, 2011, 62 pages.
U.S. Appl. No. 12/175,182, Notice of Allowability, dated Mar. 9, 2011, S pages.
U.S. Appl. No. 10/374,000, Office Action, dated Aug. 28, 2007, 8 pages.
U.S. Appl. No. 10/374,000, Office Action, dated Feb. 13, 2006, 7 pages.
U.S. Appl. No. 10/374,000, Office Action, dated Feb. 28, 2007, 8 pages.
U.S. Appl. No. 10/374,000, Office Action, dated Jul. 28, 2006, 8 pages.
U.S. Appl. No. 10/374,000, Office Action, dated Mar. 20, 2008, 6 pages.
U.S. Appl. No. 10/374,000, Office Action, dated May 20, 2009, 9 pages.
U.S. Appl. No. 10/374,000, Response to Office Action, filed Jun. 20, 2008, 8 pages.
U.S. Appl. No. 10/374,000, Response to Office Action, filed Mar. 30, 2009, 11 pages.
U.S. Appl. No. 10/374,000, Response to Office Action, filed May 12, 2006, 7 pages.
U.S. Appl. No. 10/374,000, Response to Office Action, filed May 29, 2007, 2006, 11 pages.
U.S. Appl. No. 10/374,000, Response to Office Action, filed Sep. 21, 2009, 13 pages.
U.S. Appl. No. 11/320,223, Office Action, dated Feb. 13, 2008, 11 pages.
U.S. Appl. No. 11/320,223, Office Action, dated Jan. 21, 2010, 8 pages.
U.S. Appl. No. 11/368,954, Interview Summary Communication from the USPTO, dated May 12, 2010, 3 pages.
U.S. Appl. No. 11/368,954, Office Action, dated Jan. 27, 2010, 7 pages.
U.S. Appl. No. 11/368,954, Preliminary Amendment, filed Dec. 19, 2007, 9 pages.
U.S. Appl. No. 11/380,124, Office Action, dated Apr. 26, 2010, 7 pages.
U.S. Appl. No. 11/380,124, Office Action, dated Sep. 21, 2009, 8 pages.
U.S. Appl. No. 11/380,124, Office Action, dated Jan. 16, 2009, 10 pages.
U.S. Appl. No. 11/380,621, Office Action, dated Jan. 14, 2010, 17 pages.
U.S. Appl. No. 11/380,621, Office Action, dated Jul. 1, 2009, 16 pages.
U.S. Appl. No. 11/380,621, Office Action, dated Jun. 6, 2008, 16 pages.
U.S. Appl. No. 11/725,287, Declaration of Interference, dated Nov. 10, 2011, 5 pages.
U.S. Appl. No. 11/725,287, Notice of Allowance, dated Aug. 29, 2009, 4 pages.
U.S. Appl. No. 11/725,287, Office Action, dated Dec. 7, 2010, 4 pages.
U.S. Appl. No. 11/725,287, Office Action, dated Mar. 29, 2010, 7 pages.
U.S. Appl. No. 11/725,287, Office Action, dated Dec. 3, 2008, 7 pages.
U.S. Appl. No. 11/725,287, Office Action, dated Jun. 12, 2009, 5 pages.
U.S. Appl. No. 11/725,287, Office Action, dated Oct. 5, 2011, 6 pages.
U.S. Appl. No. 11/725,287, Response, filed Feb. 24, 2009, 9 pages.
U.S. Appl. No. 11/725,287, Response, filed Jan. 6, 2011, 10 pages.
U.S. Appl. No. 11/725,287, Response, filed Jul. 28, 2009, 4 pages.
U.S. Appl. No. 11/725,287, Response, filed Sep. 29, 2010, 10 pages.
U.S. Appl. No. 11/725,287, Response, dated Oct. 11, 2011, 5 pages.
U.S. Appl. No. 12/023,280, Office Action, dated Jul. 23, 2009, 11 pages.
U.S. Appl. No. 12/023,280, Office Action, dated Oct. 5, 2009, 9 pages.
U.S. Appl. No. 12/143,377, Office Action, dated Apr. 27, 2009, 6 pages.
U.S. Appl. No. 12/143,377, Office Action, dated Feb. 4, 2010, 15 pages.
U.S. Appl. No. 12/143,377, Office Action, dated Oct. 19, 2009, 9 pages.
U.S. Appl. No. 12/143,377, Office Action, dated Sep. 13, 2010, 17 pages.
U.S. Appl. No. 12/143,377, Response, dated Aug. 27, 2009, 7 pages.
U.S. Appl. No. 12/143,377, Response, filed Jan. 13, 2011, 17 pages.
U.S. Appl. No. 12/143,377, Response, filed Jan. 19, 2010, 15 pages.
U.S. Appl. No. 12/143,377, Response, filed Jul. 6, 2010, 14 pages.
U.S. Appl. No. 12/175,270, Office Action, dated Jan. 5, 2011, 6 pages.
U.S. Appl. No. 12/175,270, Office Action, dated Mar. 14, 2012, 7 pages.
U.S. Appl. No. 12/175,270, Office Action, dated May 26, 2011, 6 pages.
U.S. Appl. No. 12/175,270, Office Action, dated Sep. 14, 2011, 6 pages.
U.S. Appl. No. 12/175,270, Response, filed Apr. 5, 2011, 7 pages.
U.S. Appl. No. 12/175,270, Response, filed Aug. 22, 2011, 18 pages.
U.S. Appl. No. 12/175,270, Response, filed Jan. 17, 2012, 10 pages.
U.S. Appl. No. 12/175,182, Office Action, dated Feb. 22, 2010, 6 pages.
U.S. Appl. No. 12/175,182, Office Action, dated Jul. 22, 2010, 7 pages.
U.S. Appl. No. 12/175,182, Office Action, dated Sep. 3, 2009, 7 pages.
U.S. Appl. No. 12/175,182, Response, filed Dec. 3, 2009, 13 pages.
U.S. Appl. No. 12/175,182, Response, filed Jan. 24, 2011, 13 pages.
U.S. Appl. No. 12/175,182, Response, filed Jun. 22, 2010, 14 pages.
U.S. Appl. No. 12/419,957, Office Action, dated Jun. 30, 2009, 6 pages.
U.S. Appl. No. 12/419,957, Office Action, dated Feb. 18, 2010, 6 pages.
U.S. Appl. No. 12/420,007, Office Action, dated Feb. 18, 2010, 9 pages.
U.S. Appl. No. 12/420,007, Office Action, dated Jul. 14, 2009, 7 pages.
U.S. Appl. No. 13/088,762, Office Action, dated Nov. 8, 2013, 10 pages.
U.S. Appl. No. 13/088,762, Response, filed May 7, 2014, 13 pages.
U.S. Appl. No. 13/088,762, Office Action, dated Jul. 31, 2014, 9 pages.
U.S. Appl. No. 13/088,762, Response, filed Sep. 30, 2014, 4 pages.
U.S. Appl. No. 13/088,762, Office Action, dated Oct. 9, 2014, 9 pages.
U.S. Appl. No. 13/088,762, Response, filed Jan. 9, 2015, 4 pages.
U.S. Appl. No. 13/088,762, Office Action, dated Feb. 11, 2015, 6 pages.
U.S. Appl. No. 13/088,762, Response, filed Jun. 11, 2015, 2 pages.
U.S. Appl. No. 13/088,762, Office Action, dated Sep. 1, 2015, 8 pages.
U.S. Appl. No. 13/088,762, Response, filed Jan. 12, 2016, 17 pages.
U.S. Appl. No. 13/088,762, Notice of Allowance, dated Feb. 12, 2016, 6 pages.
U.S. Appl. No. 13/088,762, Notice of Allowance, dated May 6, 2016, 6 pages.
U.S. Food and Drug Administration, “Guidance for Institutional Review Boards and Clinical Investigators 1998 Update: Medical Devices.” Version Sep. 10, 2008, 13 pages.
U.S. Appl. No. 29/247,954, Notice of Allowability, dated Jul. 30, 2007, 3 pages.
U.S. Appl. No. 29/247,954, Office Action, dated Apr. 6, 2007, 6 pages.
U.S. Appl. No. 60/658,518, filed Mar. 4, 2005, publicly accessible Oct. 5, 2006, 62 pages.
Urquiola, Javier, et al., “Using Lead Foil as a Radiopaque Marker for Computerized Tomography Imaging When Implant Treatment Planning,” The Journal of Prosthetic Dentistry, vol. 77, No. 2, Feb. 1997, pp. 227-228.
Vergara, et al., “Adverse Reactions to Contrast Media in CT: Effects of Temperature and Ionic Property.” Radiology, vol. 199, No. 2, May 1996, 4 pages.
Vogelzang, Robert L., “Power Injection Through Central Venous Catheters: Physiological and Hemodynamic Considerations.” The McGaw Medical Center of Northwestern University, Feinberg School of Medicine, 3 pages.
Wells, S. “Venous Access in Oncology and Haematology Patients: Part One.” Nursing Standard, vol. 22, No. 52, pp. 39-46, Sep. 3, 2008, 9 pages.
Williamson, et al., “Assessing the Adequacy of Peripherally Inserted Central Catheters for Power Injection of Intravenous Contrast Agents for CT.” Journal of Computer Assisted Tomography, vol. 6, No. 6, pp. 932-937, 2001, 6 pages.
European Search Report issued with Published Patent Application in co-pending European Patent Application No. EP17193828. 12 pages (dated Apr. 25, 2018).
U.S. Appl. No. 60/658,518, filed Mar. 4, 2005, 62 pages. (D1 Opposition / EP 2180915).
U.S. Appl. No. 60/936,491, filed Jun. 20, 2007, 28 pages. (E2 Opposition / EP 2164559).
PCT Request received for PCT Application No. PCT/US2008/67679, filed on Dec. 24, 2008, 4 pages. (E3 Opposition / EP 2164559).
Patent Assignment recorded for U.S. Appl. No. 12/143,377, on Aug. 4, 2008, 6 pages. (E4 Opposition / EP 2164559).
Transmittal letter and cover sheet for U.S. Appl. No. 60/658,518, filed Mar. 4, 2005, 2 pages. (E3 Opposition / EP 2180915).
Notice of Opposition filed for European Patent Application No. 08771600.7 on Jul. 25, 2018, 26 pages.
U.S. Appl. No. 60/961,133, filed Jul. 19, 2007, 24 pages. (E2 Opposition / EP 2180915).
Notice of Opposition filed for European Patent Application No. 08781983.5 on Jul. 4, 2018, 25 pages.
Interference Decision for Patent Interference No. 105,860, declared on Nov. 10, 2011, 9 pages. (E5 Opposition / EP 2180915).
Boswell Declaration for U.S. Pat. No. 8,257,325, issued on Sep. 4, 2012, 8 pages. (E6 Opposition / EP 2180915).
Notice of Opposition filed for European Patent Application No. 07753408.9 on Jul. 4, 2018, 24 pages.
U.S. Appl. No. 60/852,591, filed Oct. 18, 2006, 23 pages. (E2 Opposition / EP 2081634).
Guidance for Industry and FDA Staff, Use of Symbols on Labels and in Labeling of In Vitro Diagnostic Devices Intended for Professional Use, Nov. 30, 2004, 12 pages.
Guidance on Medical Device Patient Labeling; Final Guidance for Industry and FDA Reviewers, Apr. 19, 2001, 54 pages.
Reminders from FDA Regarding Ruptured Vascular Access Devices from Power Injection, Jul. 2004, 2 pages.
Stevens et al., “A Randomized, Prospective Trial of Conventional Vascular Ports vs. The Vortex “Clear-Flow” Reservoir Port in Adult Oncology Patients”, The Journal of Vascular Access Devices, 2000, pp. 37-40.
Sawyer, “Do It by Design: An Introduction to Human Factors in Medical Devices”, U.S. Department of Health and Human Services, Public Health Service, Food and Drug Administration, Center for Devices and Radiological Health, Dec. 1996, 55 pages.
Salis et al., “Maximal Flow Rates Possible during Power Injection through Currently Available PICCs: An In-Vitro Study”, Journal of the Association for Vascular Access, vol. 15, No. 3, Mar. 2004, pp. 275-281.
U.S. Appl. No. 60/675,309, filed on Apr. 27, 2005, 100 pages.
Carlson et al., “Safety Considerations in the Power Injection of Contrast Media via Central Venous Catheters During Computed Tomographic Examinations”, Investigative Radiology, vol. 27, No. 5, May 1992, pp. 337-340.
Coyle et al., “Power Injection of Contrast Media via Peripherally Inserted Central Catheters for CT”, The Journal of the Association for Vascular Access (JAVA), vol. 15, No. 8, Aug. 2004, pp. 809-814.
Herts et al., “Power Injection of Contrast Media Using Central Venous Catherters: Feasibility, Safety and Efficacy”, AJR:176(2), Feb. 2001, pp. 447-453.
Herts et al., “Power Injection of Intravenous Contrast Material Through Central Venous Catherters for CT: In Vitro Evaluations”, Radiology, vol. 200, No. 3, Sep. 1996, pp. 731-735.
IsoMed Constant-Flow Injustion System (Year:2000), 111 pages.
Signs, Symbols, and Icons: Pre-history to the Computer Age, author: Rosemary Sassoon and Albertine Gaur, first published in 1997, 1997, 3 pages.

Related Publications (2)

	Number	Date	Country
	20160367792 A1	Dec 2016	US
	20190247640 A9	Aug 2019	US

Provisional Applications (1)

	Number	Date	Country
	60961133	Jul 2007	US

Continuations (2)

	Number	Date	Country
Parent	13088762	Apr 2011	US
Child	15251122		US
Parent	12175182	Jul 2008	US
Child	13088762		US

Venous access port assembly with X-ray discernable indicia

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

CPC

Field of Search

CPC

International Classifications

Disclaimer

Term Extension

Abstract